Bicycle Therapeutics PLC Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 3,398,000 American Depositary Shares of Bicycle Therapeutics plc, representing 6.72% of the class.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 3,398,000 American Depositary Shares of Bicycle Therapeutics plc, representing 6.75% of the class.

Long Focus Capital Management and John Helmers have reported a 6.6% beneficial ownership stake in Bicycle Therapeutics PLC's American Depositary Shares.

Invus Group entities and related parties have reported beneficial ownership of 3.1% of Bicycle Therapeutics plc's ordinary shares as of March 31, 2026.

Westfield Capital Management Company, L.P. has reported a complete divestment of its common stock holdings in Bicycle Therapeutics PLC, reducing its beneficial ownership to zero percent.

Raymond Debbane and affiliated entities, including Invus Public Equities, have disclosed a combined 6.3% beneficial ownership stake in Bicycle Therapeutics plc.

Westfield Capital Management Company, L.P. has reported a complete divestment of its holdings in Bicycle Therapeutics PLC common stock.

Westfield Capital Management Company, L.P. has reported a complete divestment of its holdings in Bicycle Therapeutics PLC common stock.

Westfield Capital Management Company, L.P. reports a 6.04% beneficial ownership stake in Bicycle Therapeutics PLC as of December 31, 2025.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Bicycle Therapeutics PLC.

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported a 3.9% beneficial ownership stake in Bicycle Therapeutics PLC as of June 30, 2025.

Deep Track Capital, LP and affiliates filed an amendment to their Schedule 13G, reporting a 2.42% beneficial ownership in Bicycle Therapeutics plc.

Point72 Asset Management, L.P., along with its affiliates and Steven A. Cohen, has disclosed a beneficial ownership of 7.8% in Bicycle Therapeutics PLC, totaling 3,739,318 ordinary shares in the form of American Depositary Shares.

Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a passive 5.59% beneficial ownership stake in Bicycle Therapeutics PLC, totaling 2,672,000 American Depositary Shares.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.67% in Bicycle Therapeutics plc, totaling 2,821,171 American Depositary Shares.

Deep Track Capital, LP, along with its affiliated entities, has reported a beneficial ownership of 6.71% in Bicycle Therapeutics plc, holding 3,330,236 American Depositary Shares.

Westfield Capital Management Company, L.P. has reported a passive beneficial ownership of 5.49% of Bicycle Therapeutics PLC's common stock as of December 31, 2024.